Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Down 24.7% in December

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totalling 5,060,000 shares, a decline of 24.7% from the November 30th total of 6,720,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is currently 2.8 days.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Guggenheim dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, November 15th. Mizuho cut their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. HC Wainwright lowered their target price on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Stock Up 3.9 %

Shares of NASDAQ ADAP opened at $0.59 on Friday. The company has a market capitalization of $150.97 million, a P/E ratio of -2.68 and a beta of 2.18. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The company has a 50 day simple moving average of $0.69 and a 200-day simple moving average of $0.94. Adaptimmune Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.05.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Large investors have recently modified their holdings of the business. Baillie Gifford & Co. raised its holdings in Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after buying an additional 1,626,657 shares during the period. Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics by 15.6% during the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after acquiring an additional 1,662,184 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Adaptimmune Therapeutics by 28.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after acquiring an additional 394,566 shares during the period. FMR LLC lifted its holdings in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after acquiring an additional 50,419 shares during the last quarter. Finally, Jane Street Group LLC boosted its position in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the period. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.